RhumbLine Advisers
DERM icon

RhumbLine Advisers’s Journey Medical DERM Stock Holding History

RhumbLine Advisers’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,927
Closed -$51.2K – 4162
2026
Q1 		$51.2K Buy
10,927
+1,166
+12% +$9.05K ﹤0.01% 3584
2025
Q4 		$75.3K Sell
9,761
-1,346
-12% -$10.6K ﹤0.01% 3557
2025
Q3 		$79.1K Sell
11,107
-264
-2% -$1.92K ﹤0.01% 3579
2025
Q2 		$81.6K Buy
+11,371
New +$78.6K ﹤0.01% 3585

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

RhumbLine Advisers's DERM Position: Q2 2026 in Review

RhumbLine Advisers sold out of Journey Medical (DERM) in Q2 2026, closing a stake of 10,927 shares — an estimated $51.2K sold.

RhumbLine Advisers first reported a position in DERM in Q2 2025 and held it in 4 quarters. The position peaked at $81.6K in Q2 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

  • RhumbLine Advisers reported no remaining Journey Medical position as of Q2 2026 after selling out during the quarter.
  • RhumbLine Advisers sold 10,927 Journey Medical shares in Q2 2026, an estimated $51.2K.
  • RhumbLine Advisers first reported a position in Journey Medical in Q2 2025 and held it in 4 quarters.
  • RhumbLine Advisers's Journey Medical position peaked at $81.6K in Q2 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.